drugset / Trial / NCT00047762

Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer

NCT00047762 ↗

Phase 1 Completed Genentech, Inc.
RandomizedOpen-labelTreatment

Summary

The purpose of this study is test the safety of Tarceva, find the best dose, and see what effects (good and bad) it has on you and your colorectal cancer. The effects of Tarceva will be evaluated in combination with 5-fluorouracil, leucovorin, and irinotecan, with or without Bevacizumab.

Timeline

Start
2002-10
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody — —
Subject Erlotinib Small molecule — —

Indications